{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/65e5f047f8da17001629bf6c/65eed278356b670016ee7d46?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Transluminal angioplasty: Why was Dotter's disruptive innovation initially rejected?","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/65e5f047f8da17001629bf6c/1710150089443-b0f44d5c818ff3d9ccd285b6cab4c3da.jpeg?height=200","description":"<p>In this podcast, Chiara De Biase and Jean Marco highlight three key reasons for Charles Dotter's failure to spread his method widely in the USA. Firstly, his position as a radiologist, not a vascular surgeon; secondly, his aggressive presentation of the technique, coupled with limited patient data; and lastly, his unconventional approach to developing tools and the lack of clear objectives.</p><p>Stay tuned to discover how Dotter's method made its way to Europe in the next episode.</p>","author_name":"PCR"}